Share on StockTwits

Haemonetics (NYSE:HAE) Director Ronald Merriman sold 13,602 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $35.76, for a total transaction of $486,407.52. Following the completion of the transaction, the director now directly owns 12,105 shares of the company’s stock, valued at approximately $432,875. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Haemonetics from $38.00 to $41.00 in a research note on Thursday, July 31st. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $40.33.

Shares of Haemonetics (NYSE:HAE) opened at 36.22 on Monday. Haemonetics has a 1-year low of $29.86 and a 1-year high of $44.20. The stock has a 50-day moving average of $35.6 and a 200-day moving average of $35.03. The company has a market cap of $1.863 billion and a P/E ratio of 48.79.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.36 by $0.02. The company had revenue of $224.49 million for the quarter, compared to the consensus estimate of $215.85 million. During the same quarter in the prior year, the company posted $0.46 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, analysts predict that Haemonetics will post $1.90 earnings per share for the current fiscal year.

Haemonetics Corporation is a healthcare company engaged in providing blood management solutions to its customers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.